Fig. 6

The impact of H3K4me3 modification on immune checkpoint. (A) Alluvial diagram showing the changes of H3K4me3-lncRNA cluster, H3K4me3-lncRNA score and H3K4me3 score. (B) ROC curves of H3K4me3-lncRNA score and immune checkpoints for predicting survival of LUAD in TCGA dataset. (C) Time-dependent AUC of H3K4me3-lncRNA score and immune checkpoints for predicting 1to5-year survival. (D) The correlation matrix showed the correlation between H3K4me3 score and H3K4me3-lncRNA score and immune checkpoints. (E) Comparison of expression of immune checkpoints between high and low H3K4me3 groups. (F) Differences in H3K4me3 between high and low immune checkpoint groups. (G) The proportion of patients with high and low immune checkpoint in the two H3K4me3-lncRNA score types. (H) (I) (J) (K) (L) (M) (N) (O) Kaplan-Meier curves showing the predictive value of indicated H3K4me3 and immune checkpoint subtypes. H, survival curves based on CTLA4 expression and H3K4me3 level; I, survival curves based on ICOS expression and H3K4me3 level; J, survival curves based on TIGIT expression and H3K4me3 level; K, survival curves based on PDCD1LG2 expression and H3K4me3 level; L, survival curves based on IDO1 expression and H3K4me3 level; M, survival curves based on PDCD1 expression and H3K4me3 level; N, survival curves based on LAG3 expression and H3K4me3 level; O, survival curves based on HAVCR2 expression and H3K4me3 level. (*p < 0.05; **p < 0.01; ***p < 0.001)